Compare NXL & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXL | OSRH |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | 7 | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 18.4M |
| IPO Year | N/A | N/A |
| Metric | NXL | OSRH |
|---|---|---|
| Price | $0.40 | $0.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 208.5K | ★ 354.7K |
| Earning Date | 03-13-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.28 | N/A |
| Revenue Next Year | $185.71 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.38 |
| 52 Week High | $2.57 | $4.33 |
| Indicator | NXL | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 36.74 | 42.38 |
| Support Level | $0.37 | $0.39 |
| Resistance Level | $0.62 | $0.47 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 8.79 | 29.57 |
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.